Progress in the commercialisation of bionematicides

Abstract

In the last few years, there have been numerous developments in the commercialisation of bionematicides. Here we briefly review the commercial status of four key active ingredients backed by large international companies and which are, or are likely to become widely available soon. We also identify research priorities. While scientists have intensively researched Pasteuria spp. and Purpureocillium lilacinus as potential nematicides, little research has been done on Bacillus firmus and Myrothecium verrucaria fermentation products. Conversely, a survey of the trade press suggests that these latter two agents, particularly B. firmus, are the most widely used. There is a clear need to further understand the ecology and mode of action of B. firmus when used as a bionematicide. Furthermore, while all active ingredients have proven efficacy in laboratory and/or small plot trials, there is a paucity of independent data showing product efficacy in target markets.